Monograph
N06BA09 - Atomoxetine |
Propably not porphyrinogenic |
PNP |
Rationale
No clinical data available. Affinity for several cytochromes, but studies show no relevant CYP inductive or inhibitory properties. Based on theoretical data the drug is classified as probably not porphyrinogenic. However side effects such as anorexia, reduced appetite, nausea and vomiting are common and may be potentially porphyrinogenic through reduction in caloric intake.
Therapeutic characteristics
Centrally acting sympathomimetic. A selective and potent inhibitor of the pre-synaptic noradrenaline transporter. Adverse reactions that can mimic porphyria symptoms are abdominal pain, vomiting, nausea, irritability. These side effects may be potentially porphyrinogenic through reduction in caloric intake.
Personal communication
Report on uneventful use: One report of uneventful use of atomoxetine > 5 months in female AIP patient with known mutation. Porphyrin excretion low/normal during use. From Dr Salamanca, Madrid.
Published experience
No clinical or experimental litterature concerning atomoxetine and acute porphyria could be found.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome. Journal of Pharmacology and Experimental Therapeutics 2004; 308(2):410-418.
Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn NP, DeSante KA et al. |
14610241 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
